TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27514628

Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 3887

Group type: COMPARATOR
Intervention: Routine Medical Therapy (RMT)
Number of subjects: 3887
Study: 25394549

Group type: EXPERIMENTAL
Intervention: Abdominal massage (15 minutes, 2 times daily for 5 days)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no abdominal massage)
Number of subjects: 27
Study: 23423270

Group type: EXPERIMENTAL
Intervention: TAC-MMF
Number of subjects: 60

Group type: COMPARATOR
Intervention: CsA-MMF
Number of subjects: 60
Study: 19444295

Group type: EXPERIMENTAL
Intervention: Cataract surgery (expedited, approximately 4 weeks)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Control (routine surgery, 12 months wait)
Number of subjects: 239
Study: 18834367

Group type: EXPERIMENTAL
Intervention: Arbekacin (ABK)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (healthy volunteers)
Number of subjects: 10
Study: 16624687

Group type: EXPERIMENTAL
Intervention: Telephone case management (6 months)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 134
Study: 12730478

Group type: EXPERIMENTAL
Intervention: Iodine supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: β-carotene supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nutrition interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard antenatal interventions
Number of subjects: 0
Study: 11061773

Group type: EXPERIMENTAL
Intervention: Epinephrine inhalation
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo inhalation
Number of subjects: 19
Study: 8861677

Group type: EXPERIMENTAL
Intervention: N diet and NaHCO(3) ingestion
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Low-CHO diet and NaHCO(3) ingestion
Number of subjects: 6

Group type: COMPARATOR
Intervention: Low-CHO diet
Number of subjects: 6

Group type: COMPARATOR
Intervention: N diet and placebo
Number of subjects: 6

Group type: COMPARATOR
Intervention: Low-CHO diet and placebo
Number of subjects: 6
Study: 1739360

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 140
Study: 6135439

Group type: EXPERIMENTAL
Intervention: 1 mg (i.v.) doxazosin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 2 mg (oral) doxazosin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Doxazosin (both routes)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Doxazosin concentration
Number of subjects: 6
Study: 31337171

Group type: EXPERIMENTAL
Intervention: AAJ injection with 1.0 mL of a mixture of 0.5 mL of bupivacaine 0.5% and 0.5 mL of 20 mg of triamcinolone, plus oral placebo tablets (2 tablets every 8 hours for one week)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Systemic steroids, oral prednisolone tablets (5 mg, 2 tablets every 8 hours for one week), plus AAJ injection with 1.0 mL of a mixture of 0.5 mL of bupivacaine 0.5% and 0.5 mL of normal saline solution
Number of subjects: 60
Study: 29386173

Group type: EXPERIMENTAL
Intervention: Web-based tailored cognitive behavioral therapy (CancerCope)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Static patient education website
Number of subjects: 163
Study: 27028912

Group type: EXPERIMENTAL
Intervention: Oral 17β‐estradiol (1 mg per day, plus progesterone [45 mg] vaginal gel administered sequentially for women with a uterus)
Number of subjects: 643

Group type: COMPARATOR
Intervention: Placebo (plus sequential placebo vaginal gel for women with a uterus)
Number of subjects: 643

Group type: COMPARATOR
Intervention: Oral 17β‐estradiol and Placebo
Number of subjects: 643
Study: 25197990

Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (G1)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Inert wax material (G2)
Number of subjects: 45
Study: 22824593

Group type: COMPARATOR
Intervention: Grid laser treatment alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Single dose of intravitreal injection of ranibizumab (0.5 mg / 0.05 ml) followed by grid laser treatment on 7th day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Three loading doses of intravitreal ranibizumab at monthly intervals + standard laser treatment 7 days after the 1st injection
Number of subjects: 30
Study: 20650668

Group type: EXPERIMENTAL
Intervention: Electrical stimulation of calf muscles at rates of 2 to 120 bpm
Number of subjects: 24
Study: 17229788

Group type: EXPERIMENTAL
Intervention: Consistent use of a supervised safer injection facility (SIF)
Number of subjects: 760

Group type: COMPARATOR
Intervention: Inconsistent use of a supervised safer injection facility (SIF)
Number of subjects: 760
Study: 15346305

Group type: EXPERIMENTAL
Intervention: NASS outcome instrument
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: SF-36
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: FFbH-R
Number of subjects: 70
Study: 11665351

Group type: EXPERIMENTAL
Intervention: One Drop Only Tongue Cleaner
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tongue Scraper
Number of subjects: 30

Group type: COMPARATOR
Intervention: Toothbrush
Number of subjects: 30
Study: 9843009

Group type: EXPERIMENTAL
Intervention: 0.05% retinaldehyde cream
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 0.05% retinoic acid cream
Number of subjects: 125

Group type: COMPARATOR
Intervention: Retinaldehyde vehicle
Number of subjects: 125
Study: 7978141

Group type: COMPARATOR
Intervention: Patient-controlled analgesia regimen using morphine 1 mg.ml‐1 solution
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia regimen using morphine 1 mg.ml‐1 with metoclopramide 0.5 mg.ml‐1 solution
Number of subjects: 50
Study: 2609898

Group type: EXPERIMENTAL
Intervention: Dithranol-Biogram formulation (1% dithranol applied for 20 min after UV-B treatment)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional ex-tempore formulation (1% dithranol applied for 20 min after UV-B treatment)
Number of subjects: 33
Study: 30477834

Group type: EXPERIMENTAL
Intervention: Lipoic Acid (LA) 1200 mg daily for 2 years
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Lipoic Acid (LA)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 21
Study: 28494765

Group type: EXPERIMENTAL
Intervention: Zinc lozenges
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 26132079

Group type: EXPERIMENTAL
Intervention: DHA supplementation (3 daily fish-oil capsules, each containing 280 mg DHA, 90 mg EPA and 2 mg Vitamin E)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 24256677

Group type: EXPERIMENTAL
Intervention: Arginine vasopressin (AVP)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Catecholamines (CAs)
Number of subjects: 96
Study: 21910067

Group type: EXPERIMENTAL
Intervention: Xiongshao Capsule (XS)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 335
Study: 18373281

Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning plus tourniquet (IP-T group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group with only tourniquet application (T group)
Number of subjects: 20
Study: 16533676

Group type: EXPERIMENTAL
Intervention: Commercially produced information booklets (3 booklets provided at pre-assessment, before surgery, and at discharge)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Standard hospital information only
Number of subjects: 109
Study: 12715913

Group type: EXPERIMENTAL
Intervention: Tongue and oral mucosa cleaning (oral care) after lunch every day or every other day for two consecutive weeks
Number of subjects: 84
Study: 11061760

Group type: EXPERIMENTAL
Intervention: Surfactant treatment (Curosurf, Survanta, Alveofact, Exosurf)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Surfactant treatment
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (noninfected infants with RDS)
Number of subjects: 118
Study: 8973026

Group type: EXPERIMENTAL
Intervention: 5-week educational intervention on ADHD
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study: 1534664

Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 12
Study: 4054319

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 30842257

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 32
Study: 28147899

Group type: EXPERIMENTAL
Intervention: Cued recall condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated practice condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 27339848

Group type: EXPERIMENTAL
Intervention: Externally delivered focused ultrasound for renal denervation
Number of subjects: 69
Study: 24656142

Group type: EXPERIMENTAL
Intervention: MLVA (multilocus variable repeat analysis)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ribotyping
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Typing tests
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Laboratory turnaround time < 3 days
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Organizational factors
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Improved discrimination provided by MLVA typing
Number of subjects: 11
Study: 22721353

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 73
Study: 20089269

Group type: EXPERIMENTAL
Intervention: 500 mg ciprofloxacin twice a day for 4 weeks
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 18448709

Group type: EXPERIMENTAL
Intervention: Aggressive chemotherapy for a 65-year-old patient
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aggressive chemotherapy for a 25-year-old patient (physician role)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aggressive chemotherapy for a 25-year-old patient (abstract other role)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aggressive chemotherapy for a 25-year-old patient (self role)
Number of subjects: 0
Study: 16125527

Group type: EXPERIMENTAL
Intervention: Growth hormone plus testosterone (GH plus T) administration
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Sex steroid administration (hormone replacement therapy in women, testosterone enanthate in men)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Growth hormone administration
Number of subjects: 103
Study: 11870507

Group type: EXPERIMENTAL
Intervention: Adjuvant treatment with radioimmunotherapy in glioblastoma patients
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (glioblastoma patients)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Adjuvant treatment with radioimmunotherapy in grade III glioma patients
Number of subjects: 37
Study: 10701474

Group type: EXPERIMENTAL
Intervention: Venlafaxine XR 75-225 mg/day (n = 100)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20-60 mg/day (n = 103)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo (n = 98)
Number of subjects: 301
Study: 8784219

Group type: EXPERIMENTAL
Intervention: Clobazam (CLB)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Progabide (PGB)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OCBZ)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Flunarizine (FNR)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Milacemide (MLM)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: MK‐801
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Zonisamide (ZNS)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Dezinamide
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Loreclezole
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Nafimidone
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: ORG‐6370
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ralitoline
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Stiripentol
Number of subjects: 21
Study: 2110703

Group type: EXPERIMENTAL
Intervention: Haemophilus influenzae type b polysaccharide‐protein conjugate vaccine (PRP‐D) mixed with meningococcal and/or pneumococcal capsular polysaccharide vaccines
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Halved vaccine dose
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Multiple vaccine antigens
Number of subjects: 293
Study: 760017

Group type: EXPERIMENTAL
Intervention: Cephradine (1 g preoperatively followed by 500 mg IV q. 6 hours for 4 doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cephradine (2 g IV given approximately 1 hour before surgery)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30973790

Group type: EXPERIMENTAL
Intervention: Tamoxifen 5 mg/d
Number of subjects: 500
Study: 29354916

Group type: EXPERIMENTAL
Intervention: Fast acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Retaining needle
Number of subjects: 60
Study: 26514220

Group type: EXPERIMENTAL
Intervention: Subcutaneous local analgesic infusion (ScLAI) with bupivacaine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 15
Study: 23897696

Group type: EXPERIMENTAL
Intervention: Positive expectancy-related warning labels
Number of subjects: 40

Group type: COMPARATOR
Intervention: Health-related warning labels
Number of subjects: 40
Study: 20962656

Group type: EXPERIMENTAL
Intervention: TENS on bilateral ST36 and SP6 acupoints, continuous mode at 15 Hz, intensity of 10 mA for 30 min
Number of subjects: 52

Group type: COMPARATOR
Intervention: Non-stimulation (placebo group)
Number of subjects: 52
Study: 18488437

Group type: EXPERIMENTAL
Intervention: Combination therapy with tiotropium
Number of subjects: 61

Group type: COMPARATOR
Intervention: Theophylline alone
Number of subjects: 61
Study: 17489939

Group type: EXPERIMENTAL
Intervention: Aminophylline infusion
Number of subjects: 25
Study: 12619267

Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer/sodium fluoride toothpaste
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium fluoride toothpaste
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo toothpaste (no fluoride)
Number of subjects: 0
Study: 10867779

Group type: EXPERIMENTAL
Intervention: APOE*E4 carriers in Indian sample (aged 70 years or older)
Number of subjects: 5336

Group type: EXPERIMENTAL
Intervention: APOE*E4 carriers in US sample (aged 70 years or older)
Number of subjects: 5336

Group type: COMPARATOR
Intervention: Non-carriers of APOE*E4 in Indian sample (aged 70 years or older)
Number of subjects: 5336

Group type: COMPARATOR
Intervention: Non-carriers of APOE*E4 in US sample (aged 70 years or older)
Number of subjects: 5336
Study: 9214247

Group type: EXPERIMENTAL
Intervention: Duplex ultrasonography
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Progression of stenosis to 80% or more
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Repeated ultrasonography
Number of subjects: 715
Study: 1403593

Group type: EXPERIMENTAL
Intervention: Tetracycline fibers
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo fibers
Number of subjects: 10
Study: 3893006

Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy (ST)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Conservative therapy
Number of subjects: 107
Study: 30191302

Group type: EXPERIMENTAL
Intervention: Elective replacement of PIVC (every 72-96 hours)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Standard practice (replacement when clinically indicated)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Elective replacement of PIVC
Number of subjects: 113

Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 113
Study: 27105583

Group type: EXPERIMENTAL
Intervention: Emotion regulation training
Number of subjects: 72

Group type: COMPARATOR
Intervention: Nutrition information training
Number of subjects: 72
Study: 25468986

Group type: EXPERIMENTAL
Intervention: Full intervention group (access to point‐of‐care tests, prescriber feedback, courses for GPs, guidelines, patient information leaflets, workshops)
Number of subjects: 25479

Group type: EXPERIMENTAL
Intervention: Partial intervention group (all interventions except workshop and access to point‐of‐care tests)
Number of subjects: 25479

Group type: COMPARATOR
Intervention: Subjects requesting antibiotics (overall comparison)
Number of subjects: 25479
Study: 22512291

Group type: EXPERIMENTAL
Intervention: OBI-1
Number of subjects: 9

Group type: COMPARATOR
Intervention: Hyate:C
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 20158291

Group type: EXPERIMENTAL
Intervention: Triazolam (0.125 mg/70 kg, oral)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg/70 kg, oral)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Scopolamine (0.25 mg/70 kg, subcutaneous)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Scopolamine (0.50 mg/70 kg, subcutaneous)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 18190986

Group type: EXPERIMENTAL
Intervention: Sirolimus‐eluting stent (SES) implantation, n=65
Number of subjects: 129

Group type: COMPARATOR
Intervention: Intracoronary brachytherapy (ICBT), n=64
Number of subjects: 129
Study: 15765440

Group type: EXPERIMENTAL
Intervention: Highly experienced interpreters (N = 3)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Moderately experienced interpreters (N = 3)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Inexperienced interpreters (N = 2)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Interobserver agreement for achalasia diagnosis
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Interobserver agreement for normal motility diagnosis
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Other manometric diagnoses (DES, IEM, hypo- and hypertensive LES)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 72
Study: 12422622

Group type: EXPERIMENTAL
Intervention: Aronia in combination with apple pectin (15 g of apple pectin and 20 ml of Aronia concentrate twice daily)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (25 age-matched women with breast cancer)
Number of subjects: 42
Study: 10482930

Group type: EXPERIMENTAL
Intervention: Filgrastim-mobilized PBPC (n = 15)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Unstimulated BM (n = 14)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: PBPC (n = 15, non-randomized)
Number of subjects: 44
Study: 8621799

Group type: EXPERIMENTAL
Intervention: rHuEPO therapy
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sedentary control subjects
Number of subjects: 8
Study: 1677212

Group type: EXPERIMENTAL
Intervention: L-threonine, dosage and duration not specified
Number of subjects: 0
Study: 7037662

Group type: EXPERIMENTAL
Intervention: Pivampicillin (350 mg, three times daily for 15 days)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Ampicillin (250 mg, three times daily for 15 days)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Pivampicillin
Number of subjects: 52
Study: 30845690

Group type: EXPERIMENTAL
Intervention: Functional olive oil (FOO, 487 ppm of phenolic compounds and enriched with 389 ppm of triterpenes)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Functional olive oil (FOO)
Number of subjects: 51
Study: 27841790

Group type: COMPARATOR
Intervention: Placebo spray (saline spray)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lipid spray (phosphatidylcholine; Tears again)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lipid drop (phosphatidylglycerine; Systane Balance)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo drop (saline drop)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Symptomatic wearers with spray treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lipid drop
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ocular comfort
Number of subjects: 40
Study: 26825840

Group type: EXPERIMENTAL
Intervention: Chemotherapy with or without radiation therapy (RT) (intravaginal or pelvic)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Radiation therapy (intravaginal RT or pelvic RT) alone
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: No adjuvant treatment
Number of subjects: 85

Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Age at diagnosis
Number of subjects: 85
Study: 25224104

Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22081241

Group type: EXPERIMENTAL
Intervention: Weight loss treatment
Number of subjects: 204
Study: 19940281

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen treatment
Number of subjects: 239

Group type: COMPARATOR
Intervention: No systemic treatment
Number of subjects: 239
Study: 17588243

Group type: EXPERIMENTAL
Intervention: Funhaler (FH)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control small volume spacer
Number of subjects: 47
Study: 15175057

Group type: EXPERIMENTAL
Intervention: Left superior pulmonary vein (LSPV) isolation followed by additional isolation of the right superior pulmonary vein (RSPV) in case of AF recurrence (group A, n = 27)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Isolation of all four pulmonary veins (group B, n = 25)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Group A (LSPV isolation)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Group B (isolation of all four PVs)
Number of subjects: 52
Study: 11600257

Group type: EXPERIMENTAL
Intervention: Hyphecan (1‐4,2‐acetamide‐deoxy‐B‐D‐glucan)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Kaltostat (calcium sodium alginate)
Number of subjects: 35
Study: 9554662

Group type: EXPERIMENTAL
Intervention: Incorrect technique (spitting action)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Correct technique
Number of subjects: 20
Study: 8092508

Group type: EXPERIMENTAL
Intervention: Eltanolone 0.6 mg/kg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 8